The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)

The purpose of this study is to evaluate the efficacy and safety of 177Lu-TLX591 in patients with metastatic castration-resistant prostate cancer who have progressed following treatment with Androgen Receptor Pathway Inhibitor Treatment

Trial Details

NCT ID
NCT06520345
Phase
PHASE3
Sponsor
Telix Pharmaceuticals (Innovations) Pty Limited
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • 177Lu-TLX591
  • Enzalutamide
  • Abiraterone
  • Docetaxel
Locations (sample)
  • Orange, California, United States|33.78779,-117.85311
  • Miami, Florida, United States|25.77427,-80.19366
  • Glen Burnie, Maryland, United States|39.16261,-76.62469
  • Omaha, Nebraska, United States|41.25626,-95.94043
  • New York, New York, United States|40.71427,-74.00597

Key Eligibility Criteria

  • Be a male, at least 18 years old, with documented adenocarcinoma of the prostate defined by histological / pathological confirmation.
  • Be of ECOG Performance Status 0, 1, or 2 and have an estimated life expectancy of ≥6 months from Day 1.
  • Have metastatic disease (defined as ≥1 metastatic lesion present on baseline CT, MRI or bone scintigraphy).
  • Have castration-resistant PC (defined as disease progressing despite castration by orchiectomy or ongoing use of luteinizing hormone-releasing horm…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →